Genmab A/S logo
Genmab A/S GMAB
$ 28.2 -0.18%

Quarterly report 2022-Q2
added 08-10-2022

report update icon

Genmab A/S Income Statement 2011-2026 | GMAB

Annual Income Statement Genmab A/S

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 25 B 14.6 B 9.09 B 11.2 B 11.4 B 7.31 B 3.76 B 2.01 B 645 M -

Shares

- 630 M 630 M 613 M 608 M 599 M 585 M 563 M 510 M 460 M -

Historical Prices

33.5 33.9 22.8 17.3 20.8 19.8 12.3 7.4 4.45 1.83 0.654

Net Income

- 4.76 B 2.17 B 1.47 B 1.1 B 1.19 B 764 M 301 M 112 M -487 M -596 M

Revenue

- 10.1 B 5.37 B 3.03 B 2.37 B 1.82 B 1.13 B 850 M 664 M 485 M 351 M

Gross Profit

- - - - - - - - - - -182 M

Operating Income

- - 2.64 B 1.38 B 1.34 B - - - - - -

EBITDA

- 6.57 B 2.78 B 1.47 B 1.41 B 1.09 B 762 M 278 M 80.9 M -102 M -234 M

Operating Expenses

- - - - - - - - - - 67.9 M

General and Administrative Expenses

- 661 M 342 M 214 M 147 M 102 M 91.2 M 79.5 M 66.7 M 64.6 M 67.9 M

All numbers in DKK currency

Quarterly Income Statement Genmab A/S

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Net Income

- - - - - - 306 M - - - 3.38 B - - - 85 M - - - 261 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - 1.97 B - - - 5.45 B - - - 774 M - - - 510 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - - 787 M - - - 4.5 B - - - 137 M - - - 135 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - 787 M - - - 4.5 B - - - 137 M - - - 135 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - 1.18 B - - - 954 M - - - 637 M - - - 375 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - - - 264 M - - - 179 M - - - 73 M - - - 55.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in DKK currency

The income statement is one of the three key financial reports of a company Genmab A/S (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.64 8.07 % $ 85.4 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.66 -1.48 % $ 8.81 B australiaAustralia
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 21.36 4.86 % $ 998 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.47 5.0 % $ 378 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.92 - $ 4.81 M israelIsrael
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.19 2.7 % $ 448 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.12 -0.37 % $ 3.07 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.59 1.09 % $ 2.16 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.47 -1.34 % $ 391 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 4.25 8.35 % $ 286 B britainBritain
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.22 2.3 % $ 461 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.82 1.13 % $ 27.9 M israelIsrael
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.2 2.24 % $ 322 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA